Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea

Inclusion criteria

• Hidradenitis suppurativa:
• Adults 18 years of age and older with moderate to severe hidradenitis suppurativa who are or will be receiving Cosentyx within the scope of approved indication.
• Patients who have agreed to participate in study (written informed consent)
• Pediatric plaque psoriasis:
• Patients with moderate to severe plaque psoriasis between the ages of 6 and 18 years who are receiving or will receive Cosentyx within the scope of approved indication.
• Patients with patient or guardian consent to participate in study (written informed consent)
• Juvenile idiopathic arthritis:
• Enthesitis related arthritis and juvenile psoriatic arthritis in juvenile idiopathic arthritis category patients with enthesitis related arthritis and juvenile psoriatic arthritis in juvenile idiopathic arthritis category between the ages of 6 and 18 years and are receiving or will receive Cosentyx within the scope of approved indication.
• Patients with patient or guardian consent to participate in study (written informed consent)

Exclusion criteria

• Patients who are contraindicated according to national prescribing information
• Patients participating in other interventional clinical trials